Zydus receives USFDA nod for Isosorbide Mononitrate tablets, Health News, ET HealthWorld

[ad_1]

Ahmedabad: Zydus Lifesciences Limited received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg, on Friday.

Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease). The product will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.

The group now has 388 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

  • Published On Feb 16, 2024 at 06:19 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *